How much funding has Rib-X raised?

Rib-X has raised $209.5M in total funding, most recently a Venture Round.

Who are Rib-X's investors?

Rib-X's investors include SR One, Euclid SR Partners.

Where is Rib-X headquartered?

Rib-X is headquartered in New Haven, Connecticut, United States.

What industry is Rib-X in?

Rib-X operates in Biotech, Healthcare.

Rib-X

Closed

New Haven, United States · Founded 2000 · $209.5M raised

Biotech

Healthcare

Headquarters: New Haven, Connecticut
Founded: 2000
Business Model: B2B

Total Funding: $209.5M
Last Round: $70.0M Venture RoundFeb 2014
Rounds: 5

About

Rib-X Pharmaceuticals was an American biopharmaceutical company founded in 2000 in New Haven, Connecticut, focused on the structure-based design and development of novel broad-spectrum antibiotics to treat antibiotic-resistant infections in hospital settings. Its lead candidate, delafloxacin, was later named one of R&D Directions' 100 great investigational drugs of 2009. The company was renamed Melinta Therapeutics in 2013.

Summary

Rib-X is a Biotech company based in New Haven, United States, founded in 2000. It has raised $209.5M in total across 5 rounds, most recently a $70.0M Venture Round round in Feb 2014. Investors include SR One and Euclid SR Partners.